Researchers at the University of Pennsylvania have identified glycoprotein nonmetastatic melanoma B (GPNMB) as a key mediator in the neuron-to-neuron spread of alpha-synuclein pathology. The study, published in Neuron, reveals that microglia release GPNMB when near injured neurons, which subsequently accelerates the uptake of toxic protein aggregates by healthy cells, creating a self-reinforcing cycle of neurodegeneration.

In preclinical models, monoclonal antibodies targeting GPNMB successfully blocked the cell-to-cell transmission of alpha-synuclein. Furthermore, an analysis of 1,675 samples from the Penn Brain Bank correlated high-GPNMB genetic variants with significantly more extensive pathology in human subjects. Crucially, elevated GPNMB levels were specifically linked to Parkinson’s disease and were not observed in markers for Alzheimer's.

These results suggest that GPNMB is a viable target for disease-modifying therapy. By neutralizing this microglial protein, clinicians may be able to slow or arrest disease progression during the early stages of diagnosis, shifting the treatment paradigm from symptomatic management to the preservation of existing neuronal health.

Nxera Pharma has transitioned a non-core, undisclosed GPCR-targeted program into a new entity, Serenza Therapeutics, co-founded with a syndicate led by SV Health Investors. This allows Nxera to advance a potentially high-value asset using external Series A capital while focusing internal resources on its core metabolic and rare endocrine programs.

The deal structure includes an exclusive worldwide license (excluding Japan and select APAC territories) for Serenza to develop and commercialize the program. Nxera is eligible for up to USD $275M in development and commercial milestones plus tiered royalties, while retaining a significant minority equity stake and representation on Serenza’s board via CSO Dr. Patrik Foerch.

This "spin-out" model follows the successful precedent of Orexia Therapeutics, which was advanced through Centessa Pharmaceuticals and subsequently targeted for acquisition by Eli Lilly in a deal worth up to USD $7.8B. By utilizing its NxWave™ SBDD platform to identify validated "hits" and then offloading clinical development costs to specialized venture-backed vehicles, Nxera effectively hedges R&D risk while preserving significant downstream upside.

The FDA has granted a significant label expansion for Argenx’s Vyvgart and subcutaneous Vyvgart Hytrulo, making them the first and only therapies approved for all adult patients with generalized myasthenia gravis (gMG), regardless of antibody status. This updated indication now includes anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients, subgroups that comprise approximately 20% of the gMG population and have historically lacked targeted, approved treatment options.

Approval was supported by the Phase 3 ADAPT SERON study, which demonstrated that patients treated with efgartigimod achieved a statistically significant 3.35-point mean improvement in the MG-ADL total score at week 4 (p=0.0068) compared to placebo. The study, the largest to date in the seronegative population, confirmed rapid and sustained clinical benefits across all three studied subtypes (MuSK+, LRP4+, and triple seronegative), with a safety profile consistent with existing anti-AChR-Ab positive data.

With the removal of antibody-status restrictions, clinicians can now initiate treatment based solely on a clinical diagnosis of gMG. Argenx is currently leveraging this platform to address remaining unmet needs in the field, including ongoing clinical development for ocular MG (ADAPT OCULUS) and pediatric gMG (ADAPT Jr), aiming to establish efgartigimod as the standard of care across the full spectrum of myasthenia gravis.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Roche has entered a definitive agreement to acquire PathAI, a leader in AI-powered digital pathology, for USD $750M upfront and up to USD $300M in milestone payments. This acquisition transitions PathAI’s technology from a long-term partnership into Roche’s Diagnostics division, marking a significant consolidation in the digital pathology market.

The integration centers on PathAI’s AISight Image Management System (IMS), which converts manual tissue slide analysis into fully automated, AI-driven workflows. Beyond laboratory efficiency, the platform enhances Roche’s companion diagnostics (CDx) capabilities by utilizing AI to identify novel biomarkers and potential drug targets during clinical trials and translational research.

Subject to regulatory approval in late 2026, Roche intends to scale AISight globally. The focus is on bridging the gap between broad interventions and personalized healthcare, using high-resolution digital imaging and predictive algorithms to provide faster, data-rich diagnostic insights for oncology treatment selection and biopharma drug development.

The EU has reached a political agreement on the Critical Medicines Act, a legislative framework designed to mitigate chronic drug shortages and reduce the bloc's dependency on non-EU imports for essential therapies and Active Pharmaceutical Ingredients (APIs).

Currently, the EU produces only 25% of its required APIs, with China and India supplying 40% and 20% of volume, respectively. Under the new act, public procurement of more than 300 "critical" medicines, including insulin, morphine, and antibiotics, will no longer be based solely on price. Instead, authorities must prioritize supply security, authorized via state subsidies for local manufacturing and a "European preference" clause to incentivize production within the bloc.

The shift toward regional production is expected to increase drug prices, reflecting a "security premium" for the healthcare system. The act also institutionalizes a joint procurement mechanism, allowing groups of five or more member states to leverage the European Commission for collective purchasing. Following a final formal vote in the European Parliament, the focus will shift to balancing these increased costs against the industry's global competitiveness.